Suzhou, China – Jul 25, 2025 — Neowise Biotechnology (Suzhou) Co., Ltd. (“Neowise”), a pioneering company focused on the development of TCR-T cell therapies for solid tumors, today announced that the clinical results from its first-in-human Phase 1 investigator-initiated trial (IIT) in China of NW-301V, an autologous TCR-T cell therapy targeting KRAS G12V mutations, have been accepted for oral presentation in a Proffered Paper session at the European Society for Medical Oncology (ESMO) Congress 2025. The trial investigates preliminary safety and efficacy of NW-301V in metastatic solid tumors, including advanced colorectal and pancreatic cancers. This marks the first systematic clinical study reporting data for a TCR-T therapy targeting the KRAS G12V mutation globally.

The ESMO Congress 2025 will take place in Berlin, Germany, from October 17 to 21, 2025 (local time). Details of Neowise’s presentation are as follows:

• Title: First-in-human phase 1 study of TCR-T therapy targeting KRAS G12V in metastatic solid tumors
• Presenter: Dr. Xueli Bai, MD (The First Affiliated Hospital of Zhejiang University, China)
• Session: Proffered Paper Session: Investigational Immunotherapy
• Location: Hanover Auditorium - Hall 7.2c
• Date/Time: October 20, 2025, 10:15–11:45 (local time)
• Abstract ID: 1514O

The full abstract will be published on the ESMO website on Monday, October 13, 2025 at 00:05 CEST.

About the ESMO Congress
The European Society for Medical Oncology (ESMO) Congress is one of the most influential academic conferences in the field of oncology worldwide. Held annually, it attracts oncologists, researchers, pharmaceutical companies, and policymakers from across the globe. Organized by ESMO, the congress is dedicated to showcasing cutting-edge research, clinical trial advances, and updates to clinical practice guidelines. Covering a broad spectrum from basic research to clinical application and from solid tumors to hematologic malignancies, the ESMO Congress serves as a premier platform for shaping global cancer treatment strategies and academic exchange.

About Neowise Biotechnology
Neowise Biotechnology (Suzhou) Co., Ltd. is an innovative biotechnology company focused on the development of TCR-T cell therapies for solid tumors. The company has built a high-throughput and ultra-sensitive platform for discovering natural TCRs that specifically recognize tumor antigens. By iteratively integrating computational analyses with experimental validation, the platform efficiently screens for high-affinity tumor antigen-specific natural TCRs. This has enabled the establishment of CAST®, a globally leading experimentally validated tumor antigen-natural TCR pairing library. Several of Neowise's pipelines have advanced into clinical trials, where encouraging efficacy and favorable safety profiles have been observed across multiple solid tumor indications. For more information, please visit www.neowisebio.com.

For more information, please contact:
General inquiries: info@neowisebio.com
Collaboration and partnership: bd@neowisebio.com